Senores Pharmaceuticals Limited (senores) Q2 FY27: Revenue Up 25%, Ebitda +38%

Senores Pharmaceuticals Limited (SENORES) reports Q2 FY27 revenue up 25% and EBITDA +38%, driven by strong performance across markets.